Dr. Kerry Reynolds is a physician at the Massachusetts General Hospital Cancer Center and Instructor of Medicine at Harvard Medical School. She currently serves as the Director of the Severe Immunotherapy Complications Service, in addition to being the Clinical Director for the inpatient cancer services at Mass General Cancer Center.





Centers & Specialties

Cancer Center

Clinical Interests
  • Solid tumor oncology
  • Inpatient oncology
  • Immunotherapy toxicity
Medical Education
  • MD, University of Missouri School of Medicine
  • Residency, Massachusetts General Hospital
  • Fellowship, Dana Farber Cancer Institute
Board Certifications
  • Internal Medicine
  • Medical Oncology
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • AllWays Health (NHP) - ACD
  • AllWays Health (NHP) - PBO
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • BMC HealthNet Mass Health MCO/ACO
  • Cigna (PAL #'s)
  • Commonwealth Care Alliance
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • Maine Community Health Options (MCHO)
  • MassHealth
  • Medicare
  • Medicare - ACD
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • OSW - Vermont
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
  • Well Sense Pediatrics

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Provider Gender


Dr. Kerry Reynolds is a physician at the Massachusetts General Hospital Cancer Center and Instructor of Medicine at Harvard Medical School. She currently serves as the Director of the Severe Immunotherapy Complications Service, in addition to being the Clinical Director for the inpatient cancer services at Mass General Cancer Center.

Dr. Reynolds specializes in the care of hospitalized patients. Under her leadership, the Massachusetts General Cancer Center’s inpatient program evaluates and treats over 4,000 patients each year and serves as a core training experience for Harvard Medical School students, residents, and fellows each year.

After completing her own residency, chief residency at Massachusetts General, and fellowship training in Oncology at Dana-Farber/Partners Cancer Care, she joined the Harvard Medical School faculty in 2014, where she provides clinical care, supervises and educates trainees, participates in administrative affairs, and conducts research on severe toxicities associated with novel immunotherapy agents.

Her short-term academic and primary research focus is to create a clinical database and tissue collection infrastruction to capture the full national history of immune related adverse events (irAEs), and uncover predictors that will identify patients at highest risk for adverse events associated with immunotherapy, or those destined to be refractory.  The overall goal is to characterize these severe clinical presentations, understand the blueprint of cells/molecules driving these clinical presentations, and ultimately develop new therapeutics to improve the treatment of this unique patient population.


Research & Publications

Research Summary

We are in the midst of an exciting revolution in the treatment of cancer. By harnessing and enhancing the body’s immune system using novel therapies such as immune checkpoint inhibitors, we can reduce the amount of tumor burden in patients and, in a subset of patients and cancers, achieve long-lasting remission. However, these therapies are often limited by treatment-induced autoimmune adverse events. They affect nearly every organ system, ranging widely from minor rashes and fevers to severe gastrointestinal, pulmonary, or cardiac complications. Dr. Kerry Reynolds, along with Dr. Chloe Villani, and the Massachusetts General Hospital has taken a lead in this arena by altering our clinical practice model to provide expert multi-disciplinary care by creating the Severe Immunotherapy Complications Service. Importantly, this group is not just involved in the clinical care but they have banded together to set up infrastructure to empower specimen collection and facilitate translational research efforts, in order to understand the mechanisms driving immune-related adverse events (irAEs). Blood/tissue samples are systematically collected in an attempt to develop better therapies to treat autoimmune toxicities while maintaining anti-tumor immunity. The hope is that this will further our understanding of early mechanisms leading to autoimmune diseases and identify novel druggable targets with immunosuppressive potential.  The Severe Immunotherapy Complications Service brings together expertise from a variety of clinical divisions and scientists across the institution to coordinate our care and tackle a critical problem facing many cancer patients today. 


Selected Publications:

  • Reynolds K, et al. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist 2018 
  • Mahmood SS, Fradley MG, Cohen JV, Nohria, Reynolds, K et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 2018         
  • Chu J, Choi, J, Ostvar, S, Torchia, J, Reynolds, K et al. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair deficient metastatic colorectal  cancer. Cancer (In Press) 2018.
  • Reynolds K, et al. Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: temporal trends and clinical significance. ASCO Meeting, June, 2018.  Criss S, Kong, C, Reynolds, K. Cost-Effectiveness of Durvalumab After Chemoradiation in Stage III Non-Small Cell Lung Cancer. ISPOR Asia Pacific Meeting September, 2018. '
  • Chen ST LJ, Durbin S, Cohen JV, Reynolds K. The role of dermatology consultation in the management of dermatologic immune-related adverse effects (irAE) among hospitalized patients. SDHM, 2018.'
  • Dubey D, David, W, Amata, A, Reynolds, K, et al. Varied Phenotypes and Management of Immune Checkpoint Inhibitor Associated Submitted, 2018.


News & Events

  • 2018 ASCO Annual Meeting

    The Annual Meeting brings together oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field

  • Clinical Immuno-Oncology Symposium

    The ASCO-SITC Clinical Immuno-Oncology Symposium is a three-day meeting focused on clinical and translational research in immuno-oncology and the implications for clinical care.

  • SITC Annual Meeting

    The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy. As the largest conference solely focused on cancer immunotherapy, the Annual Meeting & Pre-Conference Programs provides more than 3,500 international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary

  • NIH Convenes Conference on Cancer, Autoimmunity and Immunology

    NCI staff, including Elad Sharon, MD, MPH, Cancer Therapy Evaluation Program (CTEP), Connie Sommers, PhD, Developmental Therapeutics Program, and Howard Young, PhD, Center for Cancer Research, as well as Marie Mancini, PhD, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and Katarzyna Bourcier, PhD, National Institute of Allergy and Infectious Diseases (NIAID), jointly organized a workshop entitled, “Cancer, Autoimmunity and Immunology.” The meeting was held March 22-23, 2018

  • Career Advancement and Leadership Skills for Women in Healthcare

    Strategies and Skills Development for Career Advancement and Leadership This professional development program delivers evidence-based strategies, skills development and education that help women at various stages of their healthcare careers step into and succeed in leadership positions. It also helps women—and men—effectively cultivate female managerial talent in healthcare settings by developing the following competencies:

  • Survey: Fewer than 30% of oncologists ‘very comfortable' treating severe immune-related adverse events

    Fewer than 30% of attending oncologists reported feeling very comfortable managing patients admitted to the hospital with severe immune-related adverse events following treatment with immune checkpoint inhibitors, according to a survey presented at the ASCO-SITC Clinical Immuno-Oncology Symposium.


MGH Cancer Center, Lawrence House
10 North Grove Street, POB 206
Boston, MA 02114-2696
Phone: 617-724-0549
Fax: 617-724-7799